Results 61 to 70 of about 266,585 (192)

The Novel ACTC1 p.Gly50Ser Variant Is Associated With Arrhythmia and Secondary Features of HCM Without Hypertrophy

open access: yesAmerican Journal of Medical Genetics Part A, Volume 200, Issue 7, Page 1742-1748, July 2026.
ABSTRACT The key diagnostic criterion for hypertrophic cardiomyopathy is the presence of otherwise unexplained hypertrophy. Current definitions of HCM rely on specific thresholds to establish a diagnosis, while guideline directed risk stratification algorithms take its magnitude into consideration.
Thomas D. Gossios   +9 more
wiley   +1 more source

A geochemical basis for endomyocardial fibrosis

open access: yes, 1986
In a search for geochemical factors that could play a role in the pathogenesis of tropical endomyocardial fibrosis, endomyocardial tissue samples obtained from patients at necropsy or operation were analysed for major elements present in laterite and ...
Valiathan, M. S.   +4 more
core   +1 more source

Does quantitative left ventricular regional wall motion change after fibrous tissue resection in endomyocardial fibrosis?

open access: yesClinics, 2009
OBJECTIVES: We compared left ventricular regional wall motion, the global left ventricular ejection fraction, and the New York Heart Association functional class pre- and postoperatively.
Vera Maria Cury Salemi   +8 more
doaj   +1 more source

Mesalazine‐Induced Myocarditis: A Challenging Diagnostic Journey

open access: yesClinical Case Reports, Volume 14, Issue 7, July 2026.
Cardiac MRI imaging showing patterns consistent with acute myocarditis. ABSTRACT Mesalazine‐induced myocarditis, though rare, should be suspected in patients presenting with acute chest pain and elevated cardiac biomarkers shortly after treatment initiation. Cardiac MRI plays a pivotal role in diagnosis. Prompt drug discontinuation often leads to rapid
Mohamed Zakaria Bouayed   +7 more
wiley   +1 more source

Presence of circulating anti-myosin antibodies in endomyocardial fibrosis. [PDF]

open access: yesPLoS Neglected Tropical Diseases, 2010
BackgroundEndomyocardial Fibrosis (EMF) is a tropical restrictive cardiomyopathy of unknown etiology with high prevalence in Sub-Saharan Africa, for which it is unclear whether the primary target of injury is the endocardial endothelium, the ...
Ana Olga Mocumbi   +2 more
doaj   +1 more source

Myocardial Immune Niches in Homeostasis and Inflammation

open access: yesImmunological Reviews, Volume 340, Issue 1, July 2026.
ABSTRACT The heart functions as a circulatory pump that supplies blood throughout the body. The execution of this critical function depends on the interplay between cardiomyocytes and the supportive cellular infrastructure, generated by endothelial cells, fibroblasts and distinct immune cell populations.
Christian Perez‐Shibayama   +6 more
wiley   +1 more source

Surgical treatment of endomyocardial fibrosis

open access: yes, 1987
Forty-six patients with endomyocardial fibrosis underwent endocardiectomy and replacement of tricuspid, mitral, or both atrioventricular valves between April, 1981, and October, 1984, at the Sree Chitra Tirunal Institute, Kerala State, India, which has a
Valiathan, M. S.   +3 more
core   +2 more sources

A Case of Right Ventricular Endomyocardial Fibrosis Presenting with Right Ventricular Failure in an Immunocompromised Patient

open access: yesJournal of Clinical and Preventive Cardiology
Endomyocardial fibrosis is a rare disease in India but an important cause of restrictive cardiomyopathy. A middle-aged nondiabetic nonhypertensive male presented to us with features of right heart failure.
Ratul Ghosh   +3 more
doaj   +1 more source

"Non parasitic hypereosinophilia revealing biventricular endomyocardial fibrosis"

open access: yesThe Pan African Medical Journal, 2018
We report a case of a 7-year-old boy, without medical history, who presented a low weight-to-height ratio associated with effort dyspnea class III and hepatalgia.
Abdelkader Jalil El Hangouche   +1 more
doaj   +1 more source

Histone Modifications in Cardiovascular Disease: Mechanisms and Therapeutic Opportunities

open access: yesMedComm, Volume 7, Issue 5, May 2026.
This graphical abstract summarizes how classical and emerging histone posttranslational modifications (PTMs), together with their chromatin regulators (writers, erasers, and readers), govern major pathobiological programs in cardiovascular disease.
Yu Zheng   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy